Skip to main content

Ciphergen s Investigation Into Revenue Issues Holds Up Q3 Financials

NEW YORK, Nov. 7 (GenomeWeb News) - Ciphergen said today that its audit committee is investigating the recognition of around $500,000 in sales recorded in the second quarter.


As a result, the company, which has enlisted the help of undisclosed "external accounting advisors," said it is delaying the release of its third-quarter financial results.


Last Wednesday, a notice on Ciphergen's web site said the company planned to issue its third-quarter earnings the following day. However, that notice had been removed when a GenomeWeb News reporter revisited the site on Thursday. A Ciphergen spokeswoman said last week the notice had been posted on the web site in error.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.